A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022)

Background MBC is a lethal form of breast cancer that arises when cancer cells invade other organs or tissues. The treatment of MBC needs personalized approaches based on the tumor and patient characteristics. The purpose of this paper is to analyze MBC studies from 2002 to 2022 using bibliometrics and to investigate its current situation, main contributors, core journals, highly cited papers, and topic evolution. Materials and methods We retrieved data from Web of Science Core Collection (WOSCC). Bibliometric analysis of the included literatures mainly used the following tools: the function of “analyze results” and “citation report” in WoS, Microsoft excel 2021, CiteSpace v.6.1. R6, VOSviewer v.1.6.18, BICOMB v.2.04 and gCLUTO v.1.0. Results We found 12,653 articles on MBC research published in 1, 802 journals by 69, 753 authors from 118 countries. The annual output and citation of MBC articles showed a rising trend over time. The United States was the most influential country in MBC research. The most cited journal in this field was The Journal of Clinical Oncology. And the most cited article was by Slamon DJ. The co-word analysis of keywords divides MBC into six research clusters. The hormone receptor-positive MBC and liquid biopsy of MBC are the frontiers research trends. “CDK4/6 inhibitor” had the highest burst strength. Conclusion Our bibliometric analysis offers a comprehensive overview of MBC research in the past two decades. It shows the current situation, main contributors, core journals, highly cited papers, and topic evolution of this field. Our study can assist researchers and practitioners to comprehend the development and trends of MBC research and to discover potential directions for future research.

[1]  B. Pistilli,et al.  Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead , 2023, Current Treatment Options in Oncology.

[2]  Shou-Ching Tang,et al.  The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options , 2022, Cancer metastasis reviews.

[3]  B. Pistilli,et al.  The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling , 2022, Cancers.

[4]  F. Cardoso,et al.  Progression-free survival and quality of life in metastatic breast cancer: The patient perspective , 2022, Breast.

[5]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Rishvanth K. Prabakar,et al.  Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib , 2022, NPJ breast cancer.

[7]  J. Lemonnier,et al.  Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer , 2021, NPJ breast cancer.

[8]  M. Somerfield,et al.  Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Curigliano,et al.  The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. , 2021, European journal of cancer.

[10]  A. Prat,et al.  Current and Future Management of HER2-Positive Metastatic Breast Cancer. , 2021, JCO oncology practice.

[11]  A. Jager,et al.  Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach , 2021, Cancers.

[12]  H. Rugo,et al.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer , 2021, Targeted Oncology.

[13]  T. Schmid,et al.  Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications , 2021, Frontiers in Oncology.

[14]  K. Hanna,et al.  Chemotherapy Treatment Considerations in Metastatic Breast Cancer , 2021, Journal of the advanced practitioner in oncology.

[15]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[16]  G. Semenza,et al.  Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1 , 2021, Cancer Research.

[17]  T. Vandenberg,et al.  Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis , 2020, Targeted Oncology.

[18]  Sung-Bae Kim,et al.  Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Le,et al.  A Co-Citation and Co-Word Analysis of Social Entrepreneurship Research , 2020 .

[20]  Gang Chen,et al.  Current Trends in Research on Bone Regeneration: A Bibliometric Analysis , 2020, BioMed research international.

[21]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[22]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[23]  M. Banys-Paluchowski,et al.  Liquid biopsy in metastatic breast cancer , 2019, Cancer drug resistance.

[24]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[25]  R. Hastings,et al.  Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer , 2019, Breast Cancer Research.

[26]  Joel S. Bader,et al.  E-cadherin is required for metastasis in multiple models of breast cancer , 2019, Nature.

[27]  S. Loi,et al.  Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis , 2019, Breast Cancer Research.

[28]  T. Fehm,et al.  The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. , 2019, Critical reviews in oncology/hematology.

[29]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[30]  E. D. de Vries,et al.  Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.

[31]  Soo-Chin Lee,et al.  CDK4-6 inhibitors in breast cancer: current status and future development , 2018, Expert opinion on drug metabolism & toxicology.

[32]  S. Mathoulin-Pélissier,et al.  Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.

[33]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[34]  T. Burki Sacituzumab govitecan activity in advanced breast cancer. , 2017, The Lancet. Oncology.

[35]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[36]  Simak Ali,et al.  Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts , 2016, Clinical Cancer Research.

[37]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[38]  A. Harlev,et al.  Bibliometrics: tracking research impact by selecting the appropriate metrics , 2016, Asian journal of andrology.

[39]  A. Tzankov,et al.  Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.

[40]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[41]  J. Silverman,et al.  HER2 in Breast Cancer: A Review and Update , 2014, Advances in anatomic pathology.

[42]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[43]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[44]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[45]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[46]  Judith Kamalski,et al.  Finding a way through the scientific literature: indexes and measures. , 2011, World neurosurgery.

[47]  G. Luisetto,et al.  Endocrine therapy of breast cancer. , 2011, Current medicinal chemistry.

[48]  J. Baselga,et al.  CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. , 2010, Clinical breast cancer.

[49]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[51]  Ludo Waltman,et al.  Software survey: VOSviewer, a computer program for bibliometric mapping , 2009, Scientometrics.

[52]  C. Hudis Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[53]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[54]  C. Parker,et al.  Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Ribatti The contribution of Gianni Bonadonna to the history of chemotherapy , 2007, Cancer Chemotherapy and Pharmacology.

[56]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[57]  Chaomei Chen,et al.  CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature , 2006, J. Assoc. Inf. Sci. Technol..

[58]  J. O’Shaughnessy Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[59]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[60]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[61]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[64]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[65]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[67]  David C Christiani,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[68]  J. Nabarro,et al.  THE NITROGEN MUSTARDS , 1950, The Journal of pharmacy and pharmacology.

[69]  T. Ishikawa,et al.  Increased intratumor heterogeneity, angiogenesis and epithelial to mesenchymal transition pathways in metaplastic breast cancer. , 2021, American journal of cancer research.

[70]  A. Soyder,et al.  The Relationship Between MRI Findings and Molecular Subtypes in Women With Breast Cancer. , 2019, Current problems in diagnostic radiology.

[71]  A. Schneeweiss,et al.  Chemotherapie desmetastasiertenMammakarzinoms – ein Anachronismus in der Ära der personalisierten zielgerichteten onkologischenTherapie ? Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy ? , 2015 .

[72]  D. Lake,et al.  High-Dose Chemotherapy in Breast Cancer , 2012, Drugs.

[73]  D. Ribnikar,et al.  Metastatic breast cancer. , 2014, Current opinion in oncology.

[74]  M. Dowsett,et al.  Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. , 2001, Cancer research.

[75]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.